#USA #Radnor #Algeness #AAT #Lanzhou Biotechnique

Advanced Aesthetic Technologies Expands in China

Advanced Aesthetic Technologies, Inc. (AAT) has made a momentous announcement regarding the approval of its flagship product, Algeness® VL, a dermal filler based on agarose gel, for marketing in China. This significant achievement highlights AAT's ongoing commitment to innovation in aesthetic medicine.

A Groundbreaking Product

The Algeness® VL dermal filler is designed specifically for facial cosmetic applications, utilizing a 2.5% agarose gel composition. It marks a pioneering advancement as the first agarose-based filler approved in China. Partnering with Lanzhou Biotechnique Development Co., Ltd. (LanDev), a subsidiary of the China National Biotec Group Company Limited, AAT has strategically positioned itself to introduce this innovative product into the rapidly growing Chinese aesthetic market.

The approval process required rigorous scientific and clinical research, culminating in the National Medical Products Administration granting a Class III import registration. This confirms Algeness® VL as a safe and effective option for patients seeking cosmetic enhancements.

A Unique Approach to Cosmetic Treatment

Algeness® is not just another filler; it is a product born out of extensive research aimed at developing a biocompatible material that effectively addresses facial volume loss and wrinkles. The technology behind Algeness® allows for a distinctive injection technique, delivering results that are both natural and aesthetically pleasing.

Doug Abel, the President and CEO of AAT, expressed his enthusiasm about entering the Chinese market stating, "We are thrilled about Algeness® making its entrance into this large aesthetic market through our partner LanDev. We believe that they are the perfect partner to maximize our success in China."

Collaboration with Leading Experts

The medical direction of Algeness® is significantly backed by prominent figures in the field. Dr. Omer Buhsem from Istanbul has acted as the medical director for Algeness® and emphasizes its unique structure and effectiveness as an essential tool in aesthetic treatments. Dr. Buhsem's retrospectives involving 700 patients underline the product’s favorable outcomes and safety profile.

Dr. Tatjana Pavicic, a dermatologist from Munich, recognizes Algeness® as a revolutionary product in aesthetic medicine. She notes its natural composition and compatibility, praising the impressive results she has archived with patients over the past decade.

Future Prospects

AAT's groundbreaking achievement won't stop here. The company has expressly outlined further milestones, including a successful clinical trial towards FDA approval in the U.S. By 2025, Comprehensive information submissions to the U.S. FDA are anticipated aiming for a pivotal move into the U.S. marketplace.

With the recent CE mark acquisition under the strict Medical Devices Regulation (MDR) and the continued investments in research and development, AAT is strategically positioned to lead innovations in aesthetic medicine.

Algeness® dermal fillers remain a unique alternative, prioritizing patient safety and efficacy by being composed of 100% natural, biodegradable materials, devoid of synthetic and cross-linking agents commonly found in competitor products. The current offering in China focuses on cosmetic improvements such as addressing nasolabial folds with broader applications planned in the future.

Conclusion

The approval of Algeness® VL in China serves as a solid foundation for AAT’s commitment to enhancing the field of aesthetic medicine globally. With its innovative technology, partnership potential, and focused growth strategies, AAT is poised to make a significant impact on the future of cosmetic treatments.

For more information about Algeness and its offerings, visit Algeness.com.